Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 403-730-1 | CAS number: 2687-96-9
Endpoint summary
Administrative data
Description of key information
A delayed contact hypersensitivity study (Kynoch, 1989) is available which is key study. This study showed that the test substance is not sensitising.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation, other
- Remarks:
- Data available from an in-vivo study performed before the requirement for an LLNA study..
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 04 to 29 Oct 1988
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study run to a method comparable with current guidelines and to GLP
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- no
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
- Species:
- guinea pig
- Strain:
- Dunkin-Hartley
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: From D. Hall, Newchurch, Staffordshire, England
- Age at study initiation:
- Weight at study initiation: 457-580 g
- Housing: Be housed in suspended cages with wire mesh floors
- Diet (e.g. ad libitum): A vitamin C-enriched was given weekly
- Water (e.g. ad libitum): They had free access to tap water
- Acclimation period: 26 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): Approximately 21℃
- Humidity (%): 30-70%
- Air changes (per hr): Approximately 15 air changes per hour
- Photoperiod (hrs dark / hrs light): Lighting was controlled by means of a time switch to give 12 hours of artificial light in each 24 hour period.
IN-LIFE DATES: From: 4 Oct 1988 To: 29 Oct 1988 - Route:
- intradermal and epicutaneous
- Vehicle:
- water
- Concentration / amount:
- Induction interadermal injection: 0.05% v/v in distilled water
Induction topical application: 2.5% v/v in distilled water
Induction topical challenge: 1% and 0.5% v/v in distilled water - Route:
- epicutaneous, occlusive
- Vehicle:
- water
- Concentration / amount:
- Induction interadermal injection: 0.05% v/v in distilled water
Induction topical application: 2.5% v/v in distilled water
Induction topical challenge: 1% and 0.5% v/v in distilled water - No. of animals per dose:
- 20 test animals
10 control animals - Details on study design:
- RANGE FINDING TESTS: The intradermal and topical irritancy of a range of dilutions of the test substance was investigated to identify (a) irritant test substance concentrations suitable for the induction phase of the main study and (b) non-irritant concentration by the topical route of administration for the challenge phase.
MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: Once (injection) and once (topical)
- Exposure period: 48 hours
- Test groups: 20 females for intradermal injections and topical application
- Control group: 10 females for intradermal injections and topical application
- Site: Scapular region
- Frequency of applications: Topical followed one week after injection
- Duration: 21 days
- Concentrations:
B. CHALLENGE EXPOSURE
- No. of exposures: Once
- Day(s) of challenge: 14 days
- Exposure period: 24 hours
- Test groups: 20 test animals
- Control group: 10 test animals
- Site: Left flank
- Concentrations: The test substance, 1% and 0.5% v/v in distilled water
- Evaluation (hr after challenge): The challenge sites were evaluated 24, 48, and 72 hours after removal of the patches.
OTHER: - Challenge controls:
- The test and control animals were challenged topically two weeks after the induction period using the test substance, 1% and 0.5% v/v in distilled water.
- Positive control substance(s):
- not specified
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 1% and 0.5% v/v
- No. with + reactions:
- 5
- Total no. in group:
- 20
- Clinical observations:
- The dermal reactions were seen in five test animals
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 1% and 0.5% v/v. No with. + reactions: 5.0. Total no. in groups: 20.0. Clinical observations: The dermal reactions were seen in five test animals.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 1% and 0.5% v/v
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No reactions were seen in all the ten animals
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 1% and 0.5% v/v. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: No reactions were seen in all the ten animals.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 1% and 0.5% v/v
- No. with + reactions:
- 5
- Total no. in group:
- 20
- Clinical observations:
- The dermal reactions were seen in five test animals
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 1% and 0.5% v/v. No with. + reactions: 5.0. Total no. in groups: 20.0. Clinical observations: The dermal reactions were seen in five test animals.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 1% and 0.5% v/v
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No reactions were seen in all the ten animals
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 1% and 0.5% v/v. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: No reactions were seen in all the ten animals.
- Reading:
- rechallenge
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- 1% and 0.5% v/v
- No. with + reactions:
- 5
- Total no. in group:
- 20
- Clinical observations:
- The dermal reactions were seen in five test animals
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 72.0. Group: test group. Dose level: 1% and 0.5% v/v. No with. + reactions: 5.0. Total no. in groups: 20.0. Clinical observations: The dermal reactions were seen in five test animals.
- Reading:
- rechallenge
- Hours after challenge:
- 72
- Group:
- negative control
- Dose level:
- 1% and 0.5% v/v
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No reactions were seen in all the ten animals
- Remarks on result:
- other: Reading: rechallenge. . Hours after challenge: 72.0. Group: negative control. Dose level: 1% and 0.5% v/v. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: No reactions were seen in all the ten animals.
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- In this screening test, performed in twenty albino guinea-pigs, the test substance produced evidence of delayed contact hypersensitivity in five animals (25%). An inconclusive response was seen in the two animals. As this value is below the CLP criteria of 30%, this study does not trigger a positive classification.
Reference
Freund's treated controls:
Guinea-pig Number |
E = Erythema O = Oedema |
Score |
|||||
24 Hours |
48 Hours |
72 Hours |
|||||
A |
P |
A |
P |
A |
P |
||
6580 |
E |
0 |
0 |
0 |
0 |
0 |
0 |
O |
0 |
0 |
0 |
0 |
0 |
0 |
|
6581 |
E |
0 |
0 |
0 |
0 |
0 |
0 |
O |
0 |
0 |
0 |
0 |
0 |
0 |
|
6582 |
E |
L1 |
0 |
L1 |
0 |
L1 |
L1 |
O |
0 |
0 |
0 |
0 |
0 |
0 |
|
6583 |
E |
1 |
0 |
1 |
0 |
1 |
0 |
O |
1 |
0 |
1 |
0 |
1 |
0 |
|
6584 |
E |
L1 |
0 |
0 |
0 |
0 |
0 |
O |
0 |
0 |
0 |
0 |
0 |
0 |
|
6585 |
E |
1 |
0 |
1 |
0 |
1 |
0 |
O |
1 |
0 |
1 |
0 |
1 |
0 |
|
6586 |
E |
L1 |
L1 |
L1 |
0 |
L1 |
0 |
O |
0 |
0 |
0 |
0 |
0 |
0 |
|
6587 |
E |
0 |
0 |
0 |
0 |
0 |
0 |
O |
0 |
0 |
0 |
0 |
0 |
0 |
|
6588 |
E |
1 |
0 |
0 |
0 |
0 |
0 |
O |
0 |
0 |
0 |
0 |
0 |
0 |
|
6589 |
E |
0 |
1 |
0 |
0 |
0 |
0 |
O |
0 |
0 |
0 |
0 |
0 |
0 |
|
L: Localised dermal reaction (restricted to a small area of the challenge site)
A: Anterior site, exposed to the test substance, 1% v/v in distilled water
P: Posterior site, exposed to the test substance, 0.5% v/v in distilled water
Test animals:
Guinea-pig Number |
E = Erythema O = Oedema |
Score |
Results Positive (+) Negative (-) Inconclusive(±) |
||||||
24 Hours |
48 Hours |
72 Hours |
|||||||
A |
P |
A |
P |
A |
P |
||||
6590 |
E |
L1 |
0 |
L1 |
0 |
L1 |
0 |
- |
|
O |
0 |
0 |
0 |
0 |
0 |
0 |
|||
6591 |
E |
2NP |
0 |
2NP |
0 |
2NP |
0 |
+
|
|
O |
1 |
0 |
1 |
0 |
1 |
0 |
|||
6592 |
E |
1 |
0 |
1* |
0 |
1* |
0 |
- |
|
O |
0 |
0 |
0 |
0 |
0 |
0 |
|||
6593 |
E |
1 |
0 |
L1 |
0 |
L1 |
0 |
- |
|
O |
0 |
0 |
0 |
0 |
0 |
0 |
|||
6594 |
E |
2 |
2 |
2NP |
2 |
2NP |
1* |
+ |
|
O |
1 |
1 |
2 |
1 |
2 |
1 |
|||
6595 |
E |
2 |
0 |
1 |
0 |
1 |
0 |
- |
|
O |
1 |
0 |
1 |
0 |
1 |
0 |
|||
6596 |
E |
2NP |
L1 |
2NP |
L1 |
N |
L1 |
+ |
|
O |
2 |
0 |
2 |
0 |
3 |
0 |
|||
6597 |
E |
2 |
1 |
1 |
0 |
2 |
0 |
+ |
|
O |
1 |
0 |
1 |
0 |
1 |
0 |
|||
6598 |
E |
0 |
0 |
0 |
0 |
0 |
0 |
- |
|
O |
0 |
0 |
0 |
0 |
0 |
0 |
|||
6599 |
E |
2 |
0 |
2 |
0 |
2 |
0 |
± |
|
O |
0 |
0 |
0 |
0 |
0 |
0 |
|||
6600 |
E |
0 |
0 |
0 |
0 |
0 |
0 |
- |
|
O |
0 |
0 |
0 |
0 |
0 |
0 |
|||
6601 |
E |
1 |
0 |
1 |
0 |
0 |
0 |
- |
|
O |
0 |
0 |
0 |
0 |
0 |
0 |
|||
6602 |
E |
0 |
0 |
0 |
0 |
0 |
0 |
- |
|
O |
0 |
0 |
0 |
0 |
0 |
0 |
|||
6603 |
E |
0 |
0 |
0 |
0 |
0 |
0 |
- |
|
O |
0 |
0 |
0 |
0 |
0 |
0 |
|||
6604 |
E |
0 |
0 |
0 |
0 |
0 |
0 |
- |
|
O |
0 |
0 |
0 |
0 |
0 |
0 |
|||
6605 |
E |
L1 |
L1 |
L1 |
0 |
0 |
0 |
± |
|
O |
0 |
0 |
0 |
0 |
0 |
0 |
|||
6606 |
E |
2 |
2 |
1 |
0 |
1 |
1* |
- |
|
O |
0 |
0 |
0 |
0 |
0 |
0 |
|||
6607 |
E |
0 |
L1 |
0 |
0 |
0 |
0 |
- |
|
O |
0 |
0 |
0 |
0 |
0 |
0 |
|||
6608 |
E |
0 |
0 |
0 |
0 |
0 |
0 |
- |
|
O |
0 |
0 |
0 |
0 |
0 |
0 |
|||
6609 |
E |
2 |
0 |
2NP |
0 |
2NP |
0 |
+ |
|
O |
1 |
0 |
2 |
0 |
2 |
0 |
|||
L: Localised dermal reaction (restricted to a small area of the challenge site)
*: Dryness and sloughing of the epidermis
NP: Necrotic patch
N: Necrosis
A: Anterior site, exposed to the test substance, 1% v/v in distilled water
P: Posterior site, exposed to the test substance, 0.5% v/v in distilled water
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
A delayed contact hypersensitivity study was conducted according to OECD 406 guideline using guinea-pig (Kynoch, 1989). Key study. In this screening test, performed in twenty albino guinea-pigs, the test substance produced evidence of delayed contact hypersensitivity in five animals (25%). An inconclusive response was seen in the two animals. As this value is below the CLP criteria of 30%, this study does not trigger a positive classification. In addition, two separate patch tests on human volunteers did not result in significant positive allergic responses.
Justification for classification or non-classification
Skin sensitisation: a delayed contact hypersensitivity study showed the test substance is a weak sensitizer, and no sensitization occurred in human patch tests. Therefore in accordance with Regulation (EC) No. 1272/2008 Table 3.4.2 the substance is not classified for this skin sensitisation endpoint. However, under the harmonized classification, index: 613 -099 -00 -6, 1-dodecyl-2-pyrrolidone is classified as Skin Sens. cat. 1.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
